A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.
Axitinib has been studied across 14 research domains including 🔬 Oncology, 🫘 Kidney, ❤️ Cardiovascular, 🛡️ Immunity, ⏳ Longevity & Aging. The primary research focus is 🔬 Oncology with 80% of studies addressing this area.
The following compounds share molecular targets with Axitinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Axitinib is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.